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1084mortality rate. Future research is needed to deter-
mine the characteristics of patients who are at risk
of MI immediately after emotional stressors and
whether speciﬁc subgroups have a worse prognosis
after MIs preceded by emotional stressors.Loes Smeijers, PhD
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Pulmonary Hypertension
for All Patients After
Shunt ClosureSuccessful repair of shunts in patients with congen-
ital heart disease (CHD) is often erroneously consid-
ered a cure, leading to a large number of patients lost
to follow-up after discharge (1). The prevalence of
pulmonary hypertension (PH) appears to be high
after shunt closure (2) and is associated withincreased morbidity and mortality (3). Until now,
only limited data on the risk of PH after shunt
closure were available, and these data were
hampered by the use of database encoded analyses,
single-center studies, or small cohort studies in
speciﬁc cardiac defects. We aimed to identify the
time course of the development of PH after shunt
closure in adults with CHD to optimize monitoring
intervals of these patients and to identify PH in an
early stage.
We used the Dutch CONgenital CORvitia registry,
containing 15,800 adult CHD patients, to identify
all patients with a closed systemic-to-pulmonary
shunt (n ¼ 3,340), of which a randomized sample,
stratiﬁed according to secondary or tertiary center,
underwent thorough review of all medical records. In
this nationwide cohort sample of 1,103 patients, we
determined the cumulative incidence of PH after
shunt closure. Subsequently, a nested case-control
study was performed to analyze predictors associ-
ated with PH after shunt closure. All cases of PH were
matched with up to 2 controls on age (5 years), sex,
and presence of Down syndrome. Presence of PH was
deﬁned as documented systolic pulmonary artery
pressure >40 mm Hg on echocardiography. Patients
with signs of left-sided valvular disease (moderate
or severe mitral stenosis or regurgitation, moderate
or severe aortic stenosis or regurgitation) or elevated
diastolic ﬁlling pressures (early diastolic velocity
ratio >15, left ventricular ejection fraction <40%,
moderate or severe left atrial dilation) were excluded.
In the cohort of 1,103 shunt patients, closure was
performed in year 1987 (median, interquartile range:
1977 to 1990) at a median age of 8.5 years (interquartile
range: 2.9 to 27.6). The most common diagnoses were
secundum atrial septal defect (ASD) (n ¼ 382), ven-
tricular septal defect (n ¼ 283), and primum ASD
(n ¼ 92). In total, 72 cases with PH were identiﬁed
during a mean period of 25  14 years. The cumula-
tive incidence of PH immediately after closure was
2.1% (95% conﬁdence interval [CI]: 0.3 to 7.7) and
>15% (95% CI: 2.6 to 23.8) 50 years after closure
(Figure 1A). Remarkably, even patients with mild
defects such as secundum ASD closed <25 years of
age, were at risk of developing PH several decades
after repair (6 of 141 patients, 4.3%). The incidence
of PH, speciﬁed according to age at closure, is
visualized in Figure 1B. In multivariate conditional
logistic regression analysis of the case-control
cohort, presence of PH pre-closure (rate ratio 5.7;
95% CI: 2.4 to 13.6; p <0.001) and New York Heart
Association functional class >I pre-closure (rate
ratio: 2.9; 95% CI: 1.3 to 6.8; p ¼ 0.009) were the
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1085strongest predictors for PH development after
closure, corrected for age at closure, sex, underlying
CHD defect, presence of right bundle branch block,
right atrial or ventricular dilation, right ventricular
dysfunction, and history of supraventricular tachy-
cardia. Furthermore, patients diagnosed with PH
had a signiﬁcantly lower 10-year survival after
diagnosis compared to their controls (odds ratio:
3.5; 95% CI: 1.2 to 10.0; p ¼ 0.02).
These ﬁndings elucidate the time course and sig-
niﬁcance of PH after shunt closure. The hypothesis
for PH development after closure might be that even
short periods of volume or pressure overload to the
pulmonary circulation result in changes of the pul-
monary vasculature, which in time lead to PH (4).
These alarming results call for monitoring of all CHD
patients after shunt closure, even when closure took
place during childhood. Our ﬁndings do not support
the current European and Northern American
guidelines, which state that patients with simple
defects such as secundum ASD, repaired when the
patient is <25 years of age, do not require regular
follow-up (5). The presented risk factors can further
aid in determining the required intensity of
monitoring in speciﬁc patients.
All patients after shunt closure need follow-up,
because even when repaired at early age, late risk
of PH development, in absence of left-sided heart
disease, is >15% and has signiﬁcant impact on
survival.0%
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NPC1L1 and Risk of
Gallstone DiseaseWe read with great interest the recent paper by Ference
et al. (1) using genetic variants in NPC1L1 (target for
ezetimibe) and HMGCR (target for statins) to predict the
effect of ezetimibe and statins on low-density
lipoprotein (LDL) cholesterol and risk of coronary heart
disease. Ezetimibe reduces plasma levels of LDL
cholesterol by inhibiting Niemann-Pick C1-like protein
1 (NPC1L1), a transporter responsible for cholesterol
uptake from the intestine into enterocytes and from bile
into hepatocytes in humans. In a recent study of
67,385 individuals from the general population (2), we
genotyped 4 common NPC1L1 variants, previously
associated with reduced LDL cholesterol levels, and
calculated a weighted genotype score. LDL cholesterol
decreased stepwise up to 3.5%, and risk of ischemic
vascular disease decreased up to 18% in those with the
highest versus lowest genotype scores. These ﬁndings
are in agreement with results from Ference et al. (1), and
a recent study on rare loss-of-function variants in
NPC1L1 (3). However, in our study, genotype score also
associated with a 22% increase in risk of symptomatic
gallstone disease. This is biologically plausible, because
in humans where NPC1L1 is expressed both in the
intestine and in the liver, inhibition of hepatic NPC1L1 is
likely to increase biliary cholesterol and the propensity
for gallstone formation. This raises the clinically relevant
question whether long-term treatment with ezetimibe
might increase the risk of gallstones. According to the
product insert of Zetia (Merck, Kenilworth, New Jersey),
treatment of dogs (which express hepatic NPC1L1) with
high doses of ezetimibe for a month increased biliary
cholesterol 2- to 4-fold (4), suggesting that a long-term,
on-target effect of ezetimibe monotherapy might be an
increased risk of gallstones. That said, it is reassuring
that 6 years of treatment with ezetimibe in combination
with a statin did not seem to increase the risk of
gallstones (5).Bo Kobberø Lauridsen, MD
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and Risk of Gallstone DiseaseDr. Lauridsen and colleagues raise the biologically plau-
siblehypothesis that inhibiting cholesterol absorption from
bile during treatmentwith ezetimibemay increase the risk
for symptomatic gallbladder disease (GBD). They report
that persons with a greater number of polymorphisms in
the NPC1L1 gene (target of ezetimibe) had lower low-
density lipoprotein cholesterol (LDL-C), a lower risk of
coronary heart disease, and a greater risk of GBD
(relative risk [RR]: 1.07; 95% conﬁdence interval [CI]:
1.02 to 1.15; p ¼ 0.02, comparing persons with scores
above and below 5) (1). On closer inspection of these
data, however, the effect of Niemann-Pick C1-like
protein 1 (NPC1L1) polymorphisms on the risk of GBD
appears to be limited to women in Copenhagen (women:
RR: 1.10; 95% CI: 1.03 to 1.19; p ¼ 0.01; men: RR: 1.00;
95%CI: 0.89 to 1.12; p¼ 0.83).
We therefore evaluated the effect of NPC1L1 poly-
morphisms on the risk of GBD among women in our
data (2). We did not ﬁnd any association between
NPC1L1 polymorphisms and the risk of GBD, either
alone or when combined with polymorphisms in the
gene that encodes the target of statins (RR: 1.02;
95% CI: 0.97 to 1.08; p ¼ 0.49, comparing persons
with NPC1L1 scores above and below median). Our
